China's pharmaceutical industry is another blue sea, the market of 10 billion smoke will rise.

Pharmaceutical Network Market Analysis: In recent years, cell therapy research and development is in full swing According to the new drug research and development monitoring database shows that up to now, China's stem cell therapy research projects accountfordate the global immunotherapy clinical research has become the world's largest market after the United StatesIt is expected that the United States alone will be expected to approve seed cell and gene therapyIt is understood that cell immunotherapy, also known as pass-cell therapy, is an immunotherapy that gives cells to patients to treat cancerFrom nonspecific immunocellular therapy in the early 1900s to recent specific immunocellular therapy, it has been technologically updated for generationsAt present, there are dozens of cell therapy products approved for market mainly concentrated in the cord hematopoietic progenitor cells and cell therapy other are: allogeneic interstitial stem cells, allogeneic cell gene modification, mytogenic cartilage cells, bone marrow source hybrid interstitial stem cells, kinyte cells and so onIn fact, with the rapid development of life science and medicine cell therapy technology has become one of the most striking areas in recent years, coupled with the construction and development of cell banks everywhere, and the resulting cell production, storage and other capacity to expand the global cell therapy market capacity is increasingIn recent years, under the influence of large-scale environmental impact, China has attached great importance to cell therapy represented by immunocellular therapy and stem cell therapy to introduce a variety of strategies to promote the research in the field of cell therapy and the healthy and orderly development of the relevant clinical industryAccording to Frost Sullivan, china's cell immunotherapy market is expected to rise from 100 million yuan a year to a compound annual growth rate of 100 million yuan per yearWith the approval of more cell immunotherapy products market is expected to reach RMB billion to annual compound annual growth rate will beIn this context, a number of cell immunotherapy enterprises have also been expanding with the industry market and leapout from paper as early as the annual release of the priority review list there are three cell drugs selected in the enterprises involved are: Shanghai Hengrun Dasheng, Kozi Biology, Galaxy BiologyIn addition, Bangyao Bio, Cree Gene, Senlang Bio, Yixi Bio, Beiheng Bio and many other enterprises in this field have also made efforts to lay outAccording to incomplete statistics, a cell immunotherapy product is undergoing clinical trials as of the beginning of the yearTwo of these products are used to treat solid tumors, including ® for the treatment of blood system cancerGlobal cell therapy is developing rapidly as a wholeIn the future, the global cell therapy industry will continue to grow as the number of clinical trials increases, government and capital support, and business partnerships increaseAt the same time, the competition between enterprises is expected to be more intense